Chemotherapy and cancer drugs – Page 2
-
BusinessCancer and rare diseases dominated 2019 drug approvals
More streamlined review processes and changing R&D priorities have contributed to sustained increase in new medicines
-
ResearchTrefoil knots steer cancer drug leads in fresh direction
Chemists look to links and knots in the search for new cancer therapies
-
ResearchDroplet screening set to accelerate immunotherapies into the clinic
Single-cell technique eliminates inefficiencies when identifying immune cells active against specific cancers
-
ResearchNew family of peptides from extremophile show antibiotic promise
Scientists isolate salinipeptins from a bacterium living in America’s Dead Sea
-
OpinionPassing through checkpoints
A new breed of cancer treatments highlights what’s possible when industry concentrates its efforts
-
BusinessCancer immunotherapy spreads rapidly
New approvals and expanded use for checkpoint inhibitor drugs illustrate the power of Nobel-winning science
-
NewsImmune-stimulating cancer treatment takes 2018 medicine Nobel
James Allison and Tasuku Honjo receive science’s highest honour for discovering how cancer stops immune cells from attacking
-
BusinessLandmark China cancer drug full approval ‘first of a wave’
Chi-Med’s fruquintinib is a result of China’s evolving drug innovation and regulation
-
ResearchArtificial intelligence seeks out new anticancer drugs
A combination of machine learning methods yields promising results for drug discovery
-
BusinessUS to invest $160m in cancer partnership
Funds will be backed up with $55m from 11 companies to advance new cancer treatments that harness the immune system
-
BusinessExpanding precision medicine beyond cancer
Exclusive interview with Koustubh Ranade, vice president of R&D at MedImmune
-
Business
BioAtla and Pfizer to collaborate on antibody research
Two-way agreement to share technology and royalties on new cancer drugs
-
-
BusinessViral cancer therapy approved in the US
T-Vec is the first approved oncolytic virus, but its limited treatment scope means it is unlikely to become a blockbuster
-
-
FeatureFast, flexible and flourishing
Paul Workman’s experiences in big pharma, academia and biotech gave him the tools to develop new drugs and spin out successful companies. Sarah Houlton profiles the 2012 Chemistry World entrepreneur of the year
-
CareersA cross-discipline MSc in cancer chemistry
A unique MSc course focuses on the cross-disciplinary know-how needed for a career in anti-cancer drug development. Joe McEntee reports
- Previous Page
- Page1
- Page2
- Next Page